Menu

Impact Events

More
Date Lead Company Event Type Approval Change Approval Likelihood
7/23/26 Johnson & Johnson (JNJ) Tecvayli for Multiple Myeloma (MM) Subscribers Only Subscribers Only Subscribers Only
7/23/26 Takeda (4502) Velcade for Multiple Myeloma (MM) Subscribers Only Subscribers Only Subscribers Only
7/23/26 Johnson & Johnson (JNJ) Talvey for Multiple Myeloma (MM) Subscribers Only Subscribers Only Subscribers Only
7/15/26 Merck & Co (MRK) Keytruda for Uterine (Endometrial) Cancer Subscribers Only Subscribers Only Subscribers Only
7/15/26 Roche (RO) Gazyva for Membranous Nephropathy Subscribers Only Subscribers Only Subscribers Only

Upcoming Catalysts

More
Expected Date Range Lead Company Drug Expected Catalyst
06/25/2025 Subscribers Only Subscribers Only Company - Analyst/R&D Update
06/25/2025 Subscribers Only Subscribers Only Company - Analyst/R&D Update
06/26/2025 Subscribers Only Subscribers Only Company - Analyst/R&D Update
09/08/2025 Subscribers Only Subscribers Only Company - Analyst/R&D Update
09/17/2025 Subscribers Only Subscribers Only Company - Analyst/R&D Update